Tag: Biopharmaceutical companies
Bluebird Bio Sold to Carlyle, SK Capital for Under $30M
Bluebird Bio, a once-promising biotech company, made headlines recently with its decision to sell itself and its portfolio of gene therapies to investment firms Carlyle and SK Capital for less than $30 million. This...
David Epstein launches new cancer startup after Novartis and Seagen career
David Epstein, who previously served as the CEO of Seagen, has launched a new cancer startup called Ottimo Pharma. The company aims to develop a drug that targets two proteins, PD-1 and VEGF, in...
BREAKING NEWS
Reforming FDA Advisory Committee Policy for Conflict of Interest-Free Decisions
Peter J. Pitts, a distinguished figure in the realm of healthcare regulation, recently shared his insights on the critical issue of FDA Advisory Committee...
